BioCentury | Oct 20, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date announced: 2014-09-08 Type: Rights offering To be raised: NOK35 million ($5.4 million) Shares: 53.8 million Price: NOK0.65 Shares outstanding prior: 285.1 million Placement agent: Carnegie Investor: Existing...
BioCentury | Oct 20, 2014
Financial News

DiaGenic completes private placement

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date completed: 2014-10-10 Type: Private placement Raised: NOK35 million ($5.4 million) Shares: 53.8 million Price: NOK0.65 Shares after offering: 285.1 million WIR Staff Diagnostic...
BioCentury | Mar 24, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Hired: Lars Christian Stugaard as acting CEO, effective April 1, while remaining CEO of Strata Marine & Offshore A/S WIR Staff Diagnostic...
BioCentury | Feb 10, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Transitioned: CFO Ruben Ekbraten to acting CEO WIR Staff Diagnostic...
BioCentury | Jan 27, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date announced: 1/22/14 Type: Rights offering To be raised: NOK50 million ($8.1 million) Shares: TBD Price: NOK0.50 Underwriter: Arctic Securities Shares outstanding prior: 8.2 million Investors: Existing investors...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

...is approved in the U.S. as an adjunct to diet to treat severe hypertriglyceridemia. 10/28/13 DiaGenic ASA...
BioCentury | Nov 4, 2013
Company News

DiaGenic diagnostic news

...Diagnostic company DiaGenic received a request from shareholders Corona Maritime A/S and Tycoon Industrier A/S to...
...Industrier A/S to convene an extraordinary general meeting to address the composition of the board. DiaGenic...
...disclose details regarding the request. The meeting must be held no later than Nov. 22. DiaGenic...
BioCentury | Nov 4, 2013
Clinical News

MCItect: Clinical trial data

...specificity. MCItect achieved 88% total accuracy amongst patients with >=1 apolipoprotein E (APOE) allele (n=25). DiaGenic...
...a validation study with MCItect will require a strategic partnership or additional funding. In July, DiaGenic...
...based on a "significantly larger and geographically more representative patient population" (see BioCentury, Sept. 2). DiaGenic ASA...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...to the liver. Delcath says FDA requested an additional trial to establish safety and efficacy DiaGenic ASA...
...partnered with Astellas Pharma Inc. (Tokyo:4503). Vical expects $13-$15M in cash burn for 2H13. 8/26/13 DiaGenic ASA...
...Not disclosed $4.6 0.68 6/30/13 $3.4 Expects headcount reductions to save over $101,424 per month. DiaGenic's...
BioCentury | Sep 2, 2013
Company News

DiaGenic diagnostic news

...DiaGenic said it will reduce headcount to reduce costs. DiaGenic said the cost reduction program is...
...longer-term corporate development. The company expects the reductions to save over NOK600,000 ($101,424) per month. DiaGenic...
...an asset or trade sale. Also following readouts from the AMYtect and MCItect clinical studies, DiaGenic...
Items per page:
1 - 10 of 44
BioCentury | Oct 20, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date announced: 2014-09-08 Type: Rights offering To be raised: NOK35 million ($5.4 million) Shares: 53.8 million Price: NOK0.65 Shares outstanding prior: 285.1 million Placement agent: Carnegie Investor: Existing...
BioCentury | Oct 20, 2014
Financial News

DiaGenic completes private placement

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date completed: 2014-10-10 Type: Private placement Raised: NOK35 million ($5.4 million) Shares: 53.8 million Price: NOK0.65 Shares after offering: 285.1 million WIR Staff Diagnostic...
BioCentury | Mar 24, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Hired: Lars Christian Stugaard as acting CEO, effective April 1, while remaining CEO of Strata Marine & Offshore A/S WIR Staff Diagnostic...
BioCentury | Feb 10, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Transitioned: CFO Ruben Ekbraten to acting CEO WIR Staff Diagnostic...
BioCentury | Jan 27, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway Business: Diagnostic Date announced: 1/22/14 Type: Rights offering To be raised: NOK50 million ($8.1 million) Shares: TBD Price: NOK0.50 Underwriter: Arctic Securities Shares outstanding prior: 8.2 million Investors: Existing investors...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

...is approved in the U.S. as an adjunct to diet to treat severe hypertriglyceridemia. 10/28/13 DiaGenic ASA...
BioCentury | Nov 4, 2013
Company News

DiaGenic diagnostic news

...Diagnostic company DiaGenic received a request from shareholders Corona Maritime A/S and Tycoon Industrier A/S to...
...Industrier A/S to convene an extraordinary general meeting to address the composition of the board. DiaGenic...
...disclose details regarding the request. The meeting must be held no later than Nov. 22. DiaGenic...
BioCentury | Nov 4, 2013
Clinical News

MCItect: Clinical trial data

...specificity. MCItect achieved 88% total accuracy amongst patients with >=1 apolipoprotein E (APOE) allele (n=25). DiaGenic...
...a validation study with MCItect will require a strategic partnership or additional funding. In July, DiaGenic...
...based on a "significantly larger and geographically more representative patient population" (see BioCentury, Sept. 2). DiaGenic ASA...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...to the liver. Delcath says FDA requested an additional trial to establish safety and efficacy DiaGenic ASA...
...partnered with Astellas Pharma Inc. (Tokyo:4503). Vical expects $13-$15M in cash burn for 2H13. 8/26/13 DiaGenic ASA...
...Not disclosed $4.6 0.68 6/30/13 $3.4 Expects headcount reductions to save over $101,424 per month. DiaGenic's...
BioCentury | Sep 2, 2013
Company News

DiaGenic diagnostic news

...DiaGenic said it will reduce headcount to reduce costs. DiaGenic said the cost reduction program is...
...longer-term corporate development. The company expects the reductions to save over NOK600,000 ($101,424) per month. DiaGenic...
...an asset or trade sale. Also following readouts from the AMYtect and MCItect clinical studies, DiaGenic...
Items per page:
1 - 10 of 44